ClinicalTrials.gg
RecruitingNCT07492992HOME-AHCLUpdated Sep 29, 2026

HOME-AHCL: Home-Based Implementation of an Advanced Hybrid Closed-Loop System With Telemonitoring in Type 1 Diabetes

An observational study in Diabetes Mellitus Type 1, sponsored by Air Liquide Healthcare Spain. Recruiting at 3 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Air Liquide Healthcare Spain (part of Air Liquide) · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Sep 29, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain — 25 open to participants now, 30 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · Spain.

Planned enrollment
25th of 36
80 · median 170
Started
2026
with 10 others
Observational
36 of 150
8 open now
Primary completion
2028-05
later than 22 of 29 live
Registered
146th of 150
by date

Among the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, this one is the 25th largest by planned enrollment of the 36 observational ones that give a count, is one of 11 that started in 2026, is one of 36 observational ones, reaches primary completion later than 22 of the 29 other live ones, and was the 146th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

25 of the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, or all of them as a file.
02

Study summary

The goal of this prospective, single-arm observational study is to characterise a home-based setup and telemonitoring care model for an advanced hybrid closed-loop insulin pump system (Tandem Control-IQ) in adults with type 1 diabetes. The study characterises safety, glycaemic outcomes, direct healthcare costs, and impact on quality of life and user experience over 12 months.

The main research questions are:

  • What is the safety profile of initiating the insulin pump system at home, measured by the percentage of sensor time spent below 54 mg/dL at 12 months?
  • What longitudinal changes in glycaemic metrics (such as Time in Range) are observed within the cohort following home-based initiation?
  • What changes in quality of life, technology satisfaction and healthcare experience are observed during follow-up?
  • What are the direct healthcare costs and resource utilization patterns associated with this care pathway from a public healthcare system perspective?

Participants will:

  • Complete an online technical training course prior to system activation.
  • Receive a home visit from a specialised nurse to configure and start the insulin pump system.
  • Have their continuous glucose monitoring data reviewed remotely every 14 days by the nursing team to manage automated clinical alerts.
  • Attend scheduled clinical follow-up assessments at 1, 3, 6, and 12 months.
  • Complete questionnaires assessing quality of life, patient experience, and device satisfaction.
Read the detailed description

The standard model for initiating Advanced Hybrid Closed-Loop (AHCL) systems in Spain is primarily hospital-centric, consuming significant healthcare resources and creating potential bottlenecks in patient access. In the Region of Murcia, high diabetes-related hospitalisation rates suggest an opportunity to optimise care delivery. The HOME-AHCL study evaluates an alternative care-delivery pathway that shifts the initiation of the Tandem Control-IQ system to the patient's home, supported by structured online education, 14-day telemonitoring with automated alerts, and shared follow-up between hospital endocrinology teams and a specialised diabetes technology care team (Novalab).

Study Pathway and Procedures:

Study activities initiated in April 2026 following ethics committee approval. The first participant signed written informed consent on 22 April 2026, and the first device was activated (Day 0) on 14 May 2026, marking the start of a 12-month staggered recruitment period planned to conclude in May 2027 (14 May 2027).

Eligible adults with type 1 diabetes undergo online technical training provided by a specialised nurse prior to system activation. The nurse subsequently conducts a home visit on Day 0 for device setup according to parameters prescribed by the hospital endocrinologist. Participants are monitored remotely every 14 days throughout the 12-month follow-up. Continuous glucose monitoring (CGM) data are reviewed fortnightly to classify automated alerts based on predefined criteria: High alerts (TIR ≤50% or TBR \<70 mg/dL ≥8%), Medium alerts (TIR >50% to \<70% or TBR \<70 mg/dL >4% to \<8%), and No alert (TIR ≥70% and TBR \<70 mg/dL ≤4%). Medium or High alerts trigger a protocolised telephone triage by specialised nurses. Technical issues are resolved directly, while persistent clinical issues are referred back to the hospital team. Scheduled data collection occurs at baseline, and at months 1, 3, 6, and 12.

Healthcare Professionals Sub-study:

Participating physicians and nurses will complete two study-specific, ad hoc questionnaires when approximately 50% of participants complete 12-month follow-up. Questionnaire 1 assesses model acceptance and feasibility; Questionnaire 2 evaluates healthcare professionals' perceptions regarding clinical time allocation and estimated resource impacts. These estimates are interpreted strictly as professional perceptions rather than objectively recorded comparative healthcare utilization data.

Data Management and Quality Assurance:

Data are prospectively collected using an electronic Case Report Form (e-CRF) hosted on the secure cloud platform ReseaArch® (Persei Vivarium, S.L.) under joint-controller GDPR compliance. Re-identification keys remain under the exclusive custody of site investigators. Missing data are expected to be minimal due to automated CGM cloud synchronization and monthly database audits.

Sample Size Assessment:

The planned sample comprises 80 participants. Assuming up to a 15% attrition rate, approximately 68 participants are expected to contribute complete 12-month primary outcome data. Given the descriptive nature of this single-arm study, statistical adequacy is based on estimation precision for the primary safety outcome: Time Below Range (TBR \<54 mg/dL at Month 12). Assuming a conservative standard deviation of 0.65 percentage points (based on real-world PLGS baseline variability), N=68 provides a 95% confidence interval precision (half-width) of approximately +/-0.15 percentage points around the mean TBR \<54 mg/dL.

Statistical Analysis Plan:

Baseline characteristics will be summarized using descriptive statistics. Longitudinal outcomes across follow-up time points (M1, M3, M6, M12) will be evaluated using mixed-effects models under the Missing at Random (MAR) assumption: Linear Mixed Models (LMM) with AR(1) or Compound Symmetry covariance structures (selected by AIC) for continuous CGM and PROM/PREM metrics, and Generalized Linear Mixed Models (GLMM) with a logit link function for dichotomous consensus targets. Centre, sex, age, duration of diabetes, and baseline BMI will be considered as prespecified potential fixed-effect covariates in adjusted analyses; their inclusion in individual models will depend on their clinical relevance to the outcome and on whether they can be meaningfully estimated given the available data. Because all participants transition systematically from FreeStyle Libre 2 at baseline to Dexcom G7 upon AHCL initiation, baseline-to-follow-up CGM comparisons are considered exploratory due to platform-time confounding; post-initiation longitudinal analyses utilize Dexcom G7 metrics exclusively. Accumulated QALYs (derived from EQ-5D-5L) will be reported descriptively within the cohort. Post-hoc pairwise comparisons will be adjusted using Bonferroni correction.

Cost Analysis:

Resource utilization (consultations, emergency visits, admissions, consumables) will be measured and valued using official regional tariffs. This allows to conduct a cost analysis from the public healthcare system perspective (Servicio Murciano de Salud), considering direct medical costs over a 1-year time horizon, and thus without discounting. In the absence of a concurrent comparator, no incremental cost analysis or economic evaluation (such as cost/effectiveness analysis) will be performed.

03

Conditions studied

  • Diabetes Mellitus Type 1

Keywords

  • Type 1 Diabetes
  • Advanced Hybrid Closed Loop
  • Insulin Pump
  • Continuous Glucose Monitoring
  • Telemonitoring
  • Remote Patient Monitoring
  • Value-Based Healthcare
  • Home Care Services
  • Quality of Life
  • Healthcare Resource Utilization
  • Partial Economic Evaluation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population consists of adults with type 1 diabetes receiving routine clinical care at public hospitals located in the Region of Murcia, Spain. To minimize selection bias, eligible patients will be invited to participate consecutively as they are identified as candidates for AHCL initiation during routine clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 1 diabetes.
  • Aged 18 years or older.
  • Candidate to initiate an Advanced Hybrid Closed-Loop (AHCL) system based on standard clinical criteria.
  • Access to the internet and/or a compatible smartphone to connect to the system.
  • Willingness to participate in the study and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Currently participating in another diabetes-related clinical trial.
  • Pregnant or planning to become pregnant during the study.
  • Inability to use the system autonomously (e.g., severe cognitive impairment or severe psychiatric disorders without support).
  • Medical for the use of insulin pumps or continuous glucose monitors (CGM).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • AHCL-IQ Home-based Cohort

    Adults with type 1 diabetes initiating the advanced hybrid closed-loop system (Tandem Control-IQ) in a home-based setting

06

What researchers measure

Primary outcomes

  1. Percentage of Time Below Range (TBR) <54 mg/dL

    Safety of the home-based initiation model is evaluated as the percentage of CGM time spent strictly below 54 mg/dL at the primary assessment time point of 12 months, analysed as a continuous variable. Results are interpreted with reference to the internationally recommended consensus target of \<1% as a clinical interpretive benchmark.

    Time frame: Month 12

Secondary outcomes

  1. Percentage of Time in Range (TIR) 70-180 mg/dL

    Clinical effectiveness will be characterised by measuring the percentage of time participants spend with sensor glucose levels between 70 and 180 mg/dL, as recorded by the continuous glucose monitoring (CGM) system.

    Time frame: Baseline, Month 1, Month 3, Month 6, and Month

  2. Percentage of Time Above Range (TAR)

    Clinical effectiveness will be evaluated by measuring the percentage of time participants spend with sensor glucose levels above 180 mg/dL (Level 1 and 2 hyperglycemia), as recorded by the continuous glucose monitoring (CGM) system

    Time frame: Baseline, Month 1, Month 3, Month 6, and Month 12

  3. Change in Glycated Hemoglobin (HbA1c) Levels

    Clinical effectiveness will be assessed by measuring the change in HbA1c percentage from baseline to evaluate long-term glycemic control

    Time frame: Baseline and Month 12

  4. Mean Sensor Glucose

    Mean glucose level (mg/dL) measured by the continuous glucose monitoring (CGM) system

    Time frame: Baseline, Month 1, Month 3, Month 6, and Month 12

  5. Glycemic Variability Assessed by Coefficient of Variation (CV)

    Percentage of the coefficient of variation of sensor glucose levels, used as a measure of glycemic variability

    Time frame: Baseline, Month 1, Month 3, Month 6, and Month

  6. Total Insulin Units Consumed

    Total daily units of insulin consumed by the participant via the advanced hybrid closed-loop system

    Time frame: Baseline, Month 1, Month 3, Month 6, and Month 12

  7. Percentage of Time With Active System

    Percentage of time the advanced hybrid closed-loop system is active and operating in closed-loop model

    Time frame: Baseline, Month 1, Month 3, Month 6, and Month 12

  8. Incidence of Severe Hypoglycemia

    Number of severe hypoglycemia episodes requiring assistance from another person during the follow-up period

    Time frame: 12 months

  9. Incidence of Diabetic Ketoacidosis (DKA)

    Number of episodes of diabetic ketoacidosis and related hospital admissions during the follow-up period

    Time frame: 12 months

  10. Change in Quality of Life Assessed by the ViDa1 Questionnaire

    Quality of life will be measured using the unabbreviated scale Vida con Diabetes tipo 1 (ViDa1) questionnaire, a specific instrument validated in Spain for adults with type 1 diabetes. The questionnaire consists of 34 items rated on a 5-point Likert scale (from 1 = strongly disagree to 5 = strongly agree). Scores are calculated by summing the items for each of its 4 dimensions: * Interference with life (12 items): Score ranges from 12 to 60. Higher scores indicate greater interference with daily life (a worse outcome). * Self-care (11 items): Score ranges from 11 to 55. Higher scores indicate better disease self-care (a better outcome). * Well-being (6 items): Score ranges from 6 to 30. Higher scores indicate greater physical and psychological well-being (a better outcome). * Disease worry (5 items): Score ranges from 5 to 25. Higher scores indicate greater fear and worry about the disease (a worse outcome).

    Time frame: Baseline, Month 3, Month 6, and Month 12

  11. Change in Diabetes Distress Assessed by the PAID-20 Questionnaire

    Disease burden and diabetes-related emotional distress will be measured using the unabbreviated scale, the Problem Areas In Diabetes (PAID) questionnaire. The questionnaire consists of 20 items, each rated from 0 (not a problem) to 4 (a serious problem). The scores for each item are summed and then multiplied by 1.25 to generate a total score. The total score ranges from a minimum value of 0 to a maximum value of 100. Higher scores indicate severe diabetes distress, representing a worse outcome

    Time frame: Baseline, Month 3, Month 6, and Month 12

  12. Health-Related Quality of Life Assessed by the EQ-5D-5L Questionnaire

    General health-related quality of life will be measured using the unabbreviated scale, the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The instrument consists of two parts. First, a descriptive system evaluating 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), which are used to calculate the EQ-Index score based on validated tariffs. The EQ-Index score ranges from a minimum value of 0 to a maximum value of 1. Second, a Visual Analogue Scale (VAS) rating current overall health, ranging from a minimum value of 0 (worst health you can imagine) to a maximum value of 100 (best health you can imagine). For both the EQ-Index and the VAS, higher scores indicate better health, representing a better outcome. Quality-adjusted life years (QALYs) will be calculated based on the EQ-Index score.

    Time frame: Baseline, Month 1, Month 3, Month 6, and Month 12

  13. Patient Experience Assessed by the howRwe Questionnaire

    Patient experience regarding the healthcare service and the home-based initiation model will be evaluated using the unabbreviated scale, the howRwe (How are we doing) questionnaire, which assesses the patient-staff relationship and overall system functioning. The questionnaire consists of 4 items, each rated on a 4-point scale from 0 (poor) to 3 (excellent). The scores for each item are summed to generate a total summary score. The total score ranges from a minimum value of 0 to a maximum value of 12. Higher scores indicate a better patient experience with the healthcare service, representing a better outcome

    Time frame: Month 1, Month 3, Month 6, and Month 12

  14. Device Satisfaction Assessed by the Diabetes Impact and Device Satisfaction Scale (DIDS)

    Patient satisfaction with the technology and the psychosocial impact of the treatment will be measured using the unabbreviated scale, the Diabetes Impact and Device Satisfaction (DIDS) Scale. The instrument consists of 11 items, each rated on a 10-point Likert scale. It is scored by calculating the mean of the items for its two subscales: * Device Satisfaction (7 items): The score ranges from a minimum value of 1 to a maximum value of 10. Higher scores indicate greater satisfaction with the insulin delivery device, representing a better outcome. * Diabetes Impact (4 items): The score ranges from a minimum value of 1 to a maximum value of 10. Higher scores indicate a greater negative impact of diabetes on the user's daily life (e.g., worry, sleep interruptions), representing a worse outcome.

    Time frame: Baseline, Month 3, Month 6, and Month 12

  15. Resource Consumption and Costs

    A cost analysis will be conducted by applying the unit cost to each resource used, based on the monetary value assigned by the Murcia Health Service. This includes the consumption of resources such as scheduled and unscheduled primary care visits, emergency room visits, hospital admissions, and specialized endocrinology consultations. The total cost will be the sum of the aggregated costs of each resource used. Therefore, this is a cost analysis considering only direct costs from the payer (the healthcare system) perspective. As the time horizon is one year, no discounting will be applied.

    Time frame: 12 months

Other outcomes

  1. Healthcare Professionals Acceptance and Experience

    Acceptance and experience of the participating doctors and nurses regarding the home-based initiation model will be evaluated using a study-specific, ad hoc questionnaire. This custom tool is developed by the scientific committee and includes neutral Likert-type items and free-text questions for qualitative analysis. Because it is a custom ad hoc tool, it does not yield a single standardized global score; instead, results will be reported descriptively.

    Time frame: Month 12

  2. Healthcare Professionals' Perceptions of Time and Resource Use

    Estimation of the clinical time saved in consultations and avoided visits, as perceived by the participating doctors and nurses, will be evaluated using a study-specific, ad hoc questionnaire currently under development by the scientific committee. This custom tool will list specific clinical tasks where the home-based model may liberate time, and will include free-text questions. Because it is a custom ad hoc tool in development, it will not yield a single standardized global score on a scale; instead, results will be reported descriptively.

    Time frame: Month 12

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2028, 25 months after the start.

Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 25 months is above that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Apr 2028 → May 2028 and completion Apr 2028 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 25, 2026
StartActual
Apr 22, 2026
Primary completionEst.
May 2028was Apr 2028
CompletionEst.
Sep 2028was Apr 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
2 sites added. Hospital General Universitario Santa Lucía is now Recruiting
Show 2 added (2 Spain)
  • Hospital General Universitario Reina Sofía · Murcia, Spain
  • Hospital Clínico Universitario Virgen de la Arrixaca · Murcia, Spain
Sep 29, 2026
Primary completion
Apr 2028→May 2028
Sep 29, 2026
Study completion
Apr 2028→Sep 2028
Sep 29, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time framePercentage of Time Below Range (TBR) <54 mg/dLBaseline, Month 1, Month 3, Month 6, and Month 12 → Month 12
  • DescriptionPercentage of Time Below Range (TBR) <54 mg/dL: how it is measured was reworded
Sep 29, 2026
Secondary outcomes
1 edited, 2 time frame changed, 1 added, 3 removed, 2 description edited
What changed in the outcomes
  • AddedResource Consumption and CostsTime frame: 12 months
  • RemovedPercentage of Time in Tight Range (TITR) 70-140 mg/dLTime frame: Baseline, Month 1, Month 3, Month 6, and Month 12
  • RemovedCost-Utility Indicator: Quality-Adjusted Life Years (QALYs) AccumulatedTime frame: 12 months
  • RemovedDirect Healthcare Costs and Resource ConsumptionTime frame: 12 months
  • Time framePercentage of Time in Range (TIR) 70-180 mg/dLBaseline, Month 1, Month 3, Month 6, and Month 12 → Baseline, Month 1, Month 3, Month 6, and Month
  • Time frameGlycemic Variability Assessed by Coefficient of Variation (CV)Baseline, Month 1, Month 3, Month 6, and Month 12 → Baseline, Month 1, Month 3, Month 6, and Month
  • DescriptionHealth-Related Quality of Life Assessed by the EQ-5D-5L Questionnaire: how it is measured was reworded
  • DescriptionPercentage of Time in Range (TIR) 70-180 mg/dL: how it is measured was reworded
  • Changedother outcomeBefore Healthcare Professionals Estimation of Efficiency and Saved TimeNow Healthcare Professionals' Perceptions of Time and Resource UseTime frame: Month 12
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Not yet recruiting→Recruiting
    2 sites added. Hospital General Universitario Santa Lucía is now Recruiting
    Show 2 added (2 Spain)
    • Hospital General Universitario Reina Sofía · Murcia, Spain
    • Hospital Clínico Universitario Virgen de la Arrixaca · Murcia, Spain
    Primary completion Apr 2028→May 2028
    Study completion Apr 2028→Sep 2028
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time framePercentage of Time Below Range (TBR) <54 mg/dLBaseline, Month 1, Month 3, Month 6, and Month 12 → Month 12
    • DescriptionPercentage of Time Below Range (TBR) <54 mg/dL: how it is measured was reworded
    Secondary outcomes 1 edited, 2 time frame changed, 1 added, 3 removed, 2 description edited
    What changed in the outcomes
    • AddedResource Consumption and CostsTime frame: 12 months
    • RemovedPercentage of Time in Tight Range (TITR) 70-140 mg/dLTime frame: Baseline, Month 1, Month 3, Month 6, and Month 12
    • RemovedCost-Utility Indicator: Quality-Adjusted Life Years (QALYs) AccumulatedTime frame: 12 months
    • RemovedDirect Healthcare Costs and Resource ConsumptionTime frame: 12 months
    • Time framePercentage of Time in Range (TIR) 70-180 mg/dLBaseline, Month 1, Month 3, Month 6, and Month 12 → Baseline, Month 1, Month 3, Month 6, and Month
    • Time frameGlycemic Variability Assessed by Coefficient of Variation (CV)Baseline, Month 1, Month 3, Month 6, and Month 12 → Baseline, Month 1, Month 3, Month 6, and Month
    • DescriptionHealth-Related Quality of Life Assessed by the EQ-5D-5L Questionnaire: how it is measured was reworded
    • DescriptionPercentage of Time in Range (TIR) 70-180 mg/dL: how it is measured was reworded
    • Changedother outcomeBefore Healthcare Professionals Estimation of Efficiency and Saved TimeNow Healthcare Professionals' Perceptions of Time and Resource UseTime frame: Month 12
    + 4 other changes: identifiers, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07492992
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Apr 22, 2026
Primary completion
May 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

María Martínez Mateos
Contact
maria.martinez-mateos@airliquide.com
+34 690 283 723
Carla Yago-Díez
Contact
carla.yagodiez@airliquide.com
Georgios Kyriakos
principal investigator · Hospital General Universitario Santa Lucía, Cartagena

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion